Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Alfuzosin 10 mg Once Daily in the Management of Acute Urinary Retention of Benign Prostatic Hyperplasia: A Double-Blind, Placebo-Controlled Study

Alfuzosin 10 mg Once Daily in the Management of Acute Urinary Retention of Benign Prostatic... Acute urinary retention (AUR) is regardedas the most serious hazard of untreated benign prostatichyperplasia (BPH). a-Blockers are frequently used for AURas they have proved to be of value for successful trialwithout catheter (TWOC) after AUR and to decrease theneed for BPH-related surgery. Objective: To evaluate thesignificance of alfuzosin 10 mg once daily (OD) for successfulTWOC in patients with AUR and long-term management.Patients and Methods: A total of 245 enrolledAUR patients were catheterized and randomly given eitheralfuzosin 10 mg OD or a placebo for 3 days (first phase), allthe failed patients extended their treatment for another3 days for a second TWOC (second phase). The successfulpatients from both phases were again randomly givenalfuzosin 10 mg OD or a placebo for 12 months, the outcomeswere the recurrence of AUR or the need for surgery(third phase). Results: In the first phase, alfuzosin had asignificant value for successful TWOC compared to a placebo(62.3 vs. 32.7%, p = 0.0001), in the second phase stillof significance in comparison to a placebo (32.6 vs. 9.5%,p = 0.002) while in the third phase, alfuzosin comparedto a placebo was of statistical significance regarding the reduction of the recurrence of AUR only in the first month(1.8 vs. 11.3%, p = 0.04) and the third month (3.7 vs. 16.9%,p = 0.02), also regarding decreasing the need for surgeryit was significant only in the first month (3.7 vs. 15.0%, p =0.04) and the third month only (7.4 vs. 20.7%, p = 0.04), respectively.This corresponds to a risk reduction of surgeryin the alfuzosin group of 76% in the first month and 65%in the third month. Conclusion: Alfuzosin 10 mg OD is ofvalue for successful TWOC after AUR, and a second trial ofvoiding in those who failed the first trial is recommended.It reduced the recurrence of AUR and the need of relatedsurgery especially during the first 3 months of treatment. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Urology Karger

Alfuzosin 10 mg Once Daily in the Management of Acute Urinary Retention of Benign Prostatic Hyperplasia: A Double-Blind, Placebo-Controlled Study

Current Urology , Volume 1 (1): 7 – Jan 1, 2007

Loading next page...
 
/lp/karger/alfuzosin-10-mg-once-daily-in-the-management-of-acute-urinary-Kgclm81I20
Publisher
Karger
Copyright
© 2007 S. Karger AG, Basel
ISSN
1661-7649
eISSN
1661-7657
DOI
10.1159/000106525
Publisher site
See Article on Publisher Site

Abstract

Acute urinary retention (AUR) is regardedas the most serious hazard of untreated benign prostatichyperplasia (BPH). a-Blockers are frequently used for AURas they have proved to be of value for successful trialwithout catheter (TWOC) after AUR and to decrease theneed for BPH-related surgery. Objective: To evaluate thesignificance of alfuzosin 10 mg once daily (OD) for successfulTWOC in patients with AUR and long-term management.Patients and Methods: A total of 245 enrolledAUR patients were catheterized and randomly given eitheralfuzosin 10 mg OD or a placebo for 3 days (first phase), allthe failed patients extended their treatment for another3 days for a second TWOC (second phase). The successfulpatients from both phases were again randomly givenalfuzosin 10 mg OD or a placebo for 12 months, the outcomeswere the recurrence of AUR or the need for surgery(third phase). Results: In the first phase, alfuzosin had asignificant value for successful TWOC compared to a placebo(62.3 vs. 32.7%, p = 0.0001), in the second phase stillof significance in comparison to a placebo (32.6 vs. 9.5%,p = 0.002) while in the third phase, alfuzosin comparedto a placebo was of statistical significance regarding the reduction of the recurrence of AUR only in the first month(1.8 vs. 11.3%, p = 0.04) and the third month (3.7 vs. 16.9%,p = 0.02), also regarding decreasing the need for surgeryit was significant only in the first month (3.7 vs. 15.0%, p =0.04) and the third month only (7.4 vs. 20.7%, p = 0.04), respectively.This corresponds to a risk reduction of surgeryin the alfuzosin group of 76% in the first month and 65%in the third month. Conclusion: Alfuzosin 10 mg OD is ofvalue for successful TWOC after AUR, and a second trial ofvoiding in those who failed the first trial is recommended.It reduced the recurrence of AUR and the need of relatedsurgery especially during the first 3 months of treatment.

Journal

Current UrologyKarger

Published: Jan 1, 2007

There are no references for this article.